ACME UNITED CORP - 10-Q Summary (Period Ended June 30, 1997)
Business Context and Reporting Period
This is a quarterly report (Form 10-Q) for ACME UNITED CORPORATION for the period ended June 30, 1997. The company operates in Consumer Products and Medical Products sectors. The report covers the three and six months ended June 30, 1997, comparing results to the same periods in 1996.
Key Financial Metrics
| Metric | Six Months Ended June 30, 1997 | Six Months Ended June 30, 1996 |
|---|---|---|
| Net Sales | $23,734,000 | $24,822,000 |
| Gross Profit Margin | 27.6% | 22.2% |
| Net Income | $503,000 | ($2,055,000) Loss |
| Earnings Per Share | $0.15 | ($0.62) Loss |
| Cash Flow from Operations | ($2,083,000) Used | ($1,264,000) Used |
| Total Debt (Current + Long Term) | $16,246,000 | $13,702,000 |
| Working Capital | $10,247,000 | $5,953,000 |
| Current Ratio | 1.73 | 1.48 |
Material Changes vs. Prior Period
- Profitability Turnaround: The company shifted from a net loss of $2.055 million in the first half of 1996 to a net income of $503,000 in the first half of 1997. This was driven by a significant improvement in gross profit margins (27.6% vs 22.2%) due to increased plant utilization in U.S. operations.
- One-Time Gains: Net income for the six-month period included a one-time gain of $849,000 from the sale of U.S. marketing rights for certain wound care products to Seton Healthcare International Limited.
- Expense Reduction: Selling, general, and administrative expenses decreased by $925,000 for the six-month period compared to 1996, partly due to the exclusion of the former Altenbach subsidiary and reduced severance costs.
- Debt Increase: Total debt increased by approximately $2.5 million compared to year-end 1996. While $1.7 million was paid down via the Seton sale, debt increased by $4.3 million excluding that transaction due to seasonality in the school products market.
- Cash Flow: Operating cash flow remained negative ($2.1 million used), primarily due to increases in accounts receivable and inventory, despite the net income.
Guidance, Outlook, and Risks
- Outlook: Management states that results for the first half of 1997 are not necessarily indicative of full-year results. Future debt reduction and capital expenditures are expected to be funded by inventory reduction and cash generated from operations.
- Liquidity: The company maintains a $13 million revolving line of credit in the U.S. (reducing to $9 million in the last 60 days of the year), with approximately $11.3 million currently available. Foreign subsidiaries have overdraft arrangements expiring at various times in 1997.
- Risks and Contingencies:
- Seasonality: Debt levels are influenced by the seasonality of the school products market.
- Asset Sales: The decline in Medical Products revenue was attributed to the sale of the Seton product line.
- Accounting Changes: The company is evaluating the impact of new FASB statements (SFAS 130 and 131) effective for the year ending December 31, 1998.
Investor Verification Checklist
- Verify the sustainability of the improved gross profit margins (27.6%) without the one-time gain from the Seton sale.
- Confirm the ability to generate positive operating cash flow given the current negative trend driven by working capital increases.
- Monitor the utilization of the $13 million revolving credit line and the impact of its reduction in the last 60 days of the calendar year.
- Assess the long-term impact of the Seton product line sale on Medical Products revenue growth.
- Review the status of foreign subsidiary overdraft arrangements expiring in 1997.